India, June 3 -- Researchers from the National Institute of Education, Nanyang Technological University, Singapore (NIE NTU, Singapore) and the Singapore-MIT Alliance for Research and Technology (SMART) have developed a fluorescent nanosensor capable of rapidly detecting indole-3-propionic acid (IPA), a gut microbiome-derived molecule increasingly studied as a marker of gut health.
In a technology validation study involving 125 human plasma samples, the sensor successfully distinguished healthy individuals from patients with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, highlighting its potential for future gut health monitoring and personalized healthcare approaches.(1)
Inflammatory Bowel Disease - Causes, Symptoms, Diagnosis, Treatment & PreventionInflammatory Bowel Disease - Causes, Symptoms, Diagnosis, Treatment & Prevention
Inflammatory bowel disease involves chronic inflammation of the colon and small intestine. Symptoms include diarrhea, abdominal pain and weight loss.
Why Scientists Are Interested in Indole-3-Propionic Acid?
Indole-3-propionic acid (IPA) is produced when gut bacteria break down tryptophan, an essential amino acid obtained through food.
Lower IPA levels have been observed in people with inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. However, measuring the metabolite has traditionally required mass spectrometry-based laboratory techniques that are costly, time-consuming, and impractical for routine screening or point-of-care use.
Researchers have associated IPA with biological processes involving inflammation and oxidative stress, making it an increasingly studied gut health biomarker.
Synbiotic Diet: How Probiotics + Prebiotics Transform Gut HealthSynbiotic Diet: How Probiotics + Prebiotics Transform Gut Health
What''s a synbiotic diet? Can synbiotic diet boost digestion, immunity, and gut balance? Learn how combining probiotics & prebiotics may help.
First Optical Nanosensor Developed for IPA Detection
The newly developed platform is reported to be the first optical nanosensor specifically engineered to detect IPA.The technology addresses a long-standing challenge in gut metabolite sensing by providing a rapid optical readout within minutes.
Using fluorescence-based sensing, the platform generates a measurable optical signal and can distinguish IPA from structurally similar metabolites commonly found in biological samples.
"This is the first time we are able to directly and rapidly measure IPA levels in biological samples using an optical nanosensor," said Assistant Professor Mervin Ang, co-first author of the study and a faculty member at NIE NTU, Singapore.
He noted that the technology provides a potential alternative to conventional laboratory techniques used for metabolite analysis.
The findings were published in Advanced Healthcare Materials in the study Fluorescent Nanosensor for Indole-3-Propionic Acid Detection in Gut Health Monitoring.
Quiz on Gut MicrobiomeQuiz on Gut Microbiome
Step into the vast realm of the gut microbiome with our interactive quiz! Ever wondered about the billions of microorganisms thriving in your digestive system? This quiz is designed to help you understand about the ...
From Agricultural Sensor Technology to Human Health Innovation
One of the most distinctive aspects of the research is the origin of the technology. The nanosensor platform evolved from SMART's earlier work on monitoring plant health, including the measurement of plant hormones and stress-related compounds.
Researchers adapted the nano-optical sensing platform for human health applications by redesigning it to recognise IPA.
This translation of agricultural sensing technology into healthcare demonstrates how innovations developed for one scientific field can be repurposed to address challenges in another.
Professor Michael Strano, corresponding author of the study, SMART DiSTAP Lead Principal Investigator, and Carbon P. Dubbs Professor of Chemical Engineering at MIT, explained that molecular recognition technologies previously used to measure metabolites in living plants were successfully adapted to tackle a long-standing challenge in gut health monitoring.
He added that focusing the technology on an important gut health biomarker enabled the team to demonstrate a tool that could eventually support more proactive and personalised approaches to healthcare.
Quiz on Crohn's DiseaseQuiz on Crohn's Disease
inflammatory bowel disease. Test your knowledge on Crohn's disease by taking this ...
Collaboration Between Engineering and Clinical Research Teams
The project brought together researchers from NIE NTU, Singapore, SMART, National University Hospital (NUH), and the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine).
By combining expertise in nanosensors, molecular recognition, gastroenterology, and translational medicine, the team was able to develop the technology and evaluate it using real patient samples. This multidisciplinary collaboration helped bridge the gap between laboratory innovation and potential clinical application.
The validation study identified measurable differences in IPA levels between healthy participants and patients with inflammatory bowel disease. Individuals experiencing active intestinal inflammation generally showed lower concentrations of the metabolite, findings that align with previous clinical observations.
"From a clinical perspective, having a rapid and minimally complex way to assess metabolite levels like IPA could be very valuable," said Adjunct Associate Professor Jonathan Lee, Senior Consultant in Gastroenterology and Hepatology at NUH and co-first author of the study.
He noted that the technology has the potential to complement existing diagnostic tools and provide additional insights into patients with inflammatory bowel diseases.
Importantly, the study does not establish that changes in IPA cause disease. Instead, it demonstrates that the sensor can detect biomarker differences associated with disease states.
Could Future Gut Health Monitoring Become More Accessible?
A notable innovation of the platform is its dual-mode sensing capability. The nanosensor operates using both visible fluorescence and near-infrared sensing.
Visible fluorescence supports rapid laboratory testing, while near-infrared sensing may enable future integration into wearable devices and continuous monitoring systems. Researchers suggest that the technology could eventually support point-of-care testing, home-based monitoring, and assessment of responses to dietary interventions or probiotics.
Unlike conventional microbiome tests that focus on identifying which bacteria are present, the nanosensor measures what those microbes are actively producing. This may provide a more functional picture of gut activity and metabolic health.
The research team has also received an Innovation to Startup (I2Start) grant to support further development and validation of the technology. Future work aims to expand the platform to detect multiple gut metabolites simultaneously and explore integration with wearable devices, microneedle systems, and microfluidic technologies.
Although larger studies are needed before clinical adoption, the findings demonstrate that rapid optical detection of a gut microbiome-derived metabolite is feasible and may contribute to future personalized health monitoring.
Why Measuring Microbial Activity Matters
Most microbiome tests identify which bacteria are present in the gut. However, the newly developed nanosensor measures what those microbes are actively producing. Researchers believe this functional approach may provide a more meaningful picture of gut health and disease activity than microbial composition alone.
What Can Readers Do Today to Support Gut Health?
While the technology is still under development, current evidence supports several habits that help maintain a healthy gut microbiome:
Eat a fiber-rich diet that includes fruits, vegetables, legumes, and whole grains.
Include fermented foods when appropriate.
Avoid unnecessary antibiotic use.
Stay physically active and maintain healthy sleep habits.
Seek medical evaluation for persistent digestive symptoms rather than relying solely on commercial gut health tests.
While the nanosensor remains an experimental technology, the study demonstrates how advances in optical sensing can move beyond the laboratory to address real-world healthcare challenges. By enabling rapid measurement of a key gut microbiome-derived molecule, the technology may help pave the way for more personalized, accessible, and function-based approaches to gut health monitoring in the future.